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Background:  Cardiopulmonary bypass surgery is often accompanied by a systemic
inflammatory response, which can lead to postoperative complications in high-risk
patients. This is mediated in part through a systemic rise in inflammatory cytokine
levels and the sequestration of leukocytes within organs. Aprotinin has previously
been shown to exert an anti-inflammatory effect by preventing the capacity of
leukocytes to transmigrate through vascular endothelium. Here we have focused on
whether aprotinin has an effect on endothelial cell activation and adhesion molecule
expression in response to tumor necrosis factor–α, particularly with reference to
whether aprotinin inhibits tumor necrosis factor–stimulated neutrophil
transendothelial migration.
Methods and Results:  Intercellular adhesion molecule–1, vascular cell adhesion
molecule–1, and E-selectin expression was studied in tumor necrosis factor–α–acti-
vated human umbilical vein endothelial cells in the presence of aprotinin at 200,
800, and 1600 kIU/mL. Aprotinin inhibited tumor necrosis factor–α–stimulated
expression of intercellular adhesion molecule–1 (P = .019 at 1600 kIU/mL) and
vascular cell adhesion molecule–1 (P = .003 at 1600 kIU/mL) but not E-selectin.
Similar results were obtained in the dermal microvascular endothelial cell line,
HMEC-1, which exhibited diminished intercellular adhesion molecule–1 expres-
sion in the presence of aprotinin (P = .040 at 800 kIU/mL and P < .001 at 1600
kIU/mL). Aprotinin also significantly inhibited neutrophil transmigration across
tumor necrosis factor–α–activated human umbilical vein endothelial cells (P = .046
at 1600 kIU/mL).
Conclusions:  We have demonstrated that aprotinin inhibits intercellular adhesion
molecule–1 and vascular cell adhesion molecule–1, but not E-selectin, expression
on tumor necrosis factor–α–activated endothelial cells and that transendothelial
migration by neutrophils is also specifically suppressed under these conditions. Our
results indicate that endothelial cells can be specifically targeted by aprotinin, there-
fore adding to our understanding of the anti-inflammatory mechanism of action of
aprotinin during cardiopulmonary bypass. 
Cardiopulmonary bypass (CPB) surgery is frequently accompaniedby a systemic inflammatory response, which can cause postopera-tive complications, lengthened duration of hospital stay, and, in theworst case scenario, multiple organ failure.1-4 The etiology of thisinflammatory response has been traced to the stress of surgery andcontact activation of platelets and leukocytes within the bypass cir-
cuit, which leads to an increase in circulating cytokine levels such as tumor necro-
sis factor (TNF)–α, interleukin-1, interleukin-6, and interleukin-8.5-7 Inflammatory
cytokines in turn cause endothelial cell (EC) activation and expression of vascular
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adhesion molecules involved in recruitment of leukocytes to
sites of inflammation or tissue injury. Acute organ injury,
which is most often observed in the ischemic lung, results
from the accumulation of neutrophils within the affected
organ and the accompanying release of histotoxic mediators
from infiltrated cells.8
Leukocyte emigration from the vasculature is governed
by an orderly series of contact events between leukocytes
and endothelium, involving adhesion molecules of the
selectin, integrin, and immunoglobulin superfamilies.9 In
general, the initial leukocyte tethering and rolling event is
mediated via the selectins E-, L-, and P-selectin, which are
specialized to carry out transient adhesive contacts under
conditions of hydrodynamic shear. The subsequent firm
adhesion step is mediated by the leukocyte integrins lym-
phocyte function–associated antigen-1, macrophage anti-
gen-l, and very late antigen-4, which recognize immuno-
globulin superfamily counter-ligands on the endothelial
surface, including intercellular adhesion molecule
(ICAM)–1, ICAM-2, and vascular cell adhesion molecule
(VCAM)–l. Least is known about the final extravasation
step, which involves contributions from the immunoglobu-
lin superfamily molecules ICAM-1, ICAM-2, and platelet
EC adhesion molecule–1, as well as leukocyte-derived pro-
teases that digest endothelial junctions and matrix barriers
ahead of the migrating cell.10
Although anti-inflammatory effects of aprotinin in CPB
have been demonstrated in clinical trials,11-13 animal mod-
els of acute lung injury,14,15 and in vitro models of neu-
trophil activation,16,17 the action of aprotinin on the leuko-
cyte-endothelial cascade remains poorly understood. We
have previously used intravital microscopy to study the
effect of aprotinin on leukocyte recruitment in response to a
topical chemoattractant, N-formyl-methyl-leucyl-phenylala-
nine, within the rat mesenteric microcirculation. These
experiments showed that aprotinin inhibited the extravasa-
tion step of the leukocyte-EC adhesion cascade but had no
effect on the rolling or firm adhesion steps.18 Parallel in
vitro experiments supported these observations by showing
that aprotinin dose-dependently inhibited neutrophil trans-
migration through human umbilical vein endothelial cell
(HUVEC) monolayers in response to the chemoattractants
N-formyl-methyl-leucyl-phenylalanine, interleukin-8, or
platelet-activating factor.18 Although this study was seen as
relevant to the sequestration of neutrophils during acute
lung injury,19,20 no in vitro model system can adequately
model the complexities of the in vivo situation, and in the
present study the emphasis has been placed on a more
endothelial cell–specific agonist, TNF-α.21
TNF-α promotes leukocyte–EC interactions by up-
regulating expression of a number of EC adhesion mole-
cules including E-selectin, ICAM-1, and VCAM-1.21 Here
we have focused on whether aprotinin inhibits the ability of
TNF to activate ECs, and, if so, whether this influences
leukocyte-EC interactions.
Methods
Reagents and Antibodies
Aprotinin, dexamethasone, gelatin, and fibronectin were pur-
chased from Sigma-Aldrich Chemical Co Ltd (Poole, Dorset,
United Kingdom). TNF-α was the gift of Dr Martyn Robinson,
Celltech Chiroscience Ltd (Slough, United Kingdom). Anti-
ICAM-1 monoclonal antibody 15.2 was the gift of Dr Nancy
Hogg, Imperial Cancer Research Fund (London, United
Kingdom). The anti-E-selectin monoclonal antibody 1.2B6 and
anti-VCAM-1 monoclonal antibody 1.4C3 were generated within
our group as previously described.22
EC Culture
HUVECs were obtained from umbilical cords by collagenase type
II (Boehringer-Mannhein, Lewes, Sussex, United Kingdom) diges-
tion, as previously described.22 Human umbilical cords were
cleaned with 70% ethanol, and the umbilical vein was identified
and flushed with Hanks balanced salt solution to remove blood.
The vein was then filled with 10 mL of 0.1% collagenase
(Boehringer) in Hanks balanced salt solution, the vessel ends
clamped, and the cord incubated for 10 minutes at 37°C. The col-
lagenase digest was retained, and the cord was flushed through
with 20 mL of Hanks balanced salt solution to collect the remain-
ing HUVECs. The ECs were pelleted by centrifugation at 200g for
5 minutes and resuspended in HUVEC growth medium consisting
of medium M199 supplemented with 20% heat-inactivated (56°C
for 30 minutes) fetal calf serum (Hyclone Laboratories Inc, Logan,
Utah), 100 IU/mL penicillin, 100 µg/mL streptomycin, 2 mmol/L
L-glutamine, 10 U/mL heparin, and 30 µg/mL EC growth factor
(Sigma) before plating out on 1% v/v gelatin coated 25-cm2 tissue
culture flasks. Once confluent, cells were passaged with trypsin
(0.5 mg/mL)–ethylenediamine tetraacetic acid (0.2 mg/mL) for 1
minute at 37°C followed by inactivation with cold phosphate-
buffered saline solution and fetal calf serum. Cells were sediment-
ed at 210g for 10 minutes at 4°C, resuspended in medium, and
transferred into gelatin-coated 75-cm2 tissue culture flasks, having
been split in a 1:2 or 1:3 ratio. The HUVECs were passaged twice
weekly and used between passages 2 and 5.
The human dermal microvascular EC line HMEC-1 (the gift of
Dr Edwin Ades, Center for Disease Control, Atlanta, Ga) was
maintained in culture medium MCDB 131 (Life Technologies,
Paisley, United Kingdom), grown to confluence, and passaged as
described above for HUVECs.
Neutrophil Isolation From Human Venous Blood
The technique used for isolation of human neutrophils has been
previously described.18 Peripheral venous blood from 5 healthy
nonsmoking human donors was anticoagulated immediately by
2 mL of sodium citrate 3.8% (Pharma Hameln, Hameln,
Germany) per 25 mL of blood and aliquoted into polypropylene
tubes. After centrifugation at 3000 rpm for 10 minutes the plas-
ma was removed, and cells were mixed with 6 mL of 6% high
molecular weight dextran (Dextran T500; Amersham-Pharmacia
Biotech, Amersham, United Kingdom) and 20 mL phosphate-
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buffered saline solution. After 25 minutes to sediment red cells,
the leukocyte-rich upper layer was harvested, centrifuged at
1200 rpm for 5 minutes, resuspended in 2 mL of autologous
plasma, and layered onto a 2-step (74% and 50%) Percoll
(Amersham-Pharmacia) gradient. After centrifugation at 1300
rpm for 10 minutes, neutrophils were collected from the top of
the 74% interface, washed twice in RPMI 1640 medium con-
taining 2% fetal calf serum, and counted.
Neutrophil Transmigration Experiments
For transmigration experiments, HUVECs were coated onto 3.0-
µm pore-size cell culture inserts (Falcon; Becton-Dickinson,
Franklin Lakes, NJ) as previously described.18 One day before
transmigration, cell culture inserts were coated with 100 µL of
phosphate-buffered saline solution containing 50 µg/mL
fibronectin for 2 hours. After excess fibronectin had been rinsed
off, inserts were placed into 24-well plates (Nunclon; Nalge Nunc
International, Roskilde, Denmark), and 1 × 105 HUVECs were
added to each insert. After overnight incubation, ECs were prein-
cubated for 60 minutes with aprotinin at 200 kIU/mL, 800 kIU/mL
or 1600 kIU/mL, or medium. So that the possible effects of apro-
tinin on neutrophils could be avoided, aprotinin was washed out
from HUVEC lawns with 2 rinses of RPMI 1640, and, subse-
quently, RPMI 1640 containing TNF-α was added at 2 ng/mL to
the lower chamber. Four and one-half hours after administration of
TNF-α, neutrophils were added at 1 × 106 to the upper surface of
filter inserts. Neutrophil transmigration was measured at 60 min-
utes by counting cells that had migrated into the lower chamber.
Each experiment was performed in duplicate and repeated 4 times
with different HUVEC and neutrophil isolates, no two isolates
being alike.
Flow Cytometric Analysis of ICAM-1, VCAM-1, and E-
Selectin Expression
HUVECs or HMEC-1 were isolated and cultured in petri dishes.
Cells were used between passages 2 and 5. At confluence, ECs
were preincubated with aprotinin at 200 kIU/mL or 1600 kIU/mL
for 60 minutes before challenge with TNF-α at 2 ng/mL. After
4.5 hours of culture in the presence of TNF-α, cells were har-
vested with trypsin (0.5 mg/mL)-ethylene diaminetetraacetic acid
(0.2 mg/mL), resuspended in medium, transferred into
polypropylene tubes, and incubated with primary antibodies
15.2, 1.4C3, and 1.2B6 for 15 minutes on ice. An isotype-
matched antibody was used as a control. Preliminary experiments
demonstrated that a time period of 4.5 hours was necessary to
achieve significant simultaneous TNF-α–induced up-regulation
of ICAM-1, VCAM-1, and E-selectin. After 3 washes with phos-
phate-buffered saline solution, fluorescein isothiocyanate cou-
pled goat anti-mouse immunoglobulin G secondary antibody was
added at the manufacturer’s recommended concentration (Sigma
Chemical Co, Dorset, United Kingdom), and incubation contin-
ued for an additional 15 minutes on ice. After 3 additional wash-
es in phosphate-buffered saline solution, flow cytometric analy-
sis was carried out with an EPICS XL flow cytometer (Coulter
Electronics Ltd, Luton, United Kingdom). The staining intensity
of each test antibody was initially corrected with respect to an
isotype-matched control antibody to obtain a relative staining
intensity (RFI). To average RFIs between experiments, it was
necessary to normalize expression relative to the control sample
(in the absence of any agonists) to correct for the natural vari-
ability in adhesion molecule expression between fresh EC iso-
lates. Final results were expressed as fold increase over control.
Figure 1. Aprotinin inhibits ICAM-1 and VCAM-1, but not E-
selectin, expression on HUVECs. HUVECs were pretreated for 60
minutes with aprotinin at the concentrations indicated, rinsed
with culture medium, and activated in the presence of 2 ng/mL
TNF-α for 4.5 hours. At the end of the culture period, HUVECs were
harvested and expression of ICAM-1 (A), VCAM-1 (B), and E-
selectin (C) was determined by flow cytometry. Results are
expressed as the mean ± SD fold increase over control.
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Statistics
The effect of aprotinin (200, 800, and 1600 kIU/mL) on TNF-
α–induced adhesion molecule expression and neutrophil transmi-
gration was analyzed with a 1-way analysis of variance in con-
junction with a Student-Neuman-Keuls post-test (SPSS Inc,
Chicago, Ill). The effect of 10–5 mol/L dexamethasone on TNF-
induced adhesion molecule expression was analyzed with a paired
t test (SPSS Inc).
Results
Aprotinin Inhibits ICAM-1 and VCAM-1, but not E-
selectin, Expression on HUVECs
Figure 1 shows the effect of aprotinin on the TNF-α–induced
expression of ICAM-1, VCAM-1, and E-selectin. All 3 adhe-
sion molecules were significantly up-regulated on HUVECs
by 4.5-hour culture in the presence of 2 ng/mL TNF-α.
Aprotinin dose-dependently inhibited expression of ICAM-1
(P = .019 at 1600 kIU/mL) (Figure 1, A) and VCAM-1 (P =
.003 at 1600 kIU/mL) (Figure 1, B), but not E-selectin (Figure
1, C). As a control, dexamethasone inhibited TNF-α–induced
expression of all 3 adhesion molecules, consistent with previ-
ous reports of its inhibitory action against NF-κB agonists.23
ICAM-1 expression in the presence of 10–5 mol/L dexametha-
sone was 60.18% ± 21.53% (P = .026) relative to TNF only,
VCAM-1 was 64.35% ± 23.81% (P = .011), and E-selectin
was 68.06% ± 21.86% (P = .020).
Aprotinin Inhibits ICAM-1 Expression in
Microvascular ECs
The dermal microvascular EC line HMEC-1 was used to
investigate whether the above results with large vessel ECs
could be extended to microvascular ECs. The results in
Figure 2 show that aprotinin dose-dependently inhibited
TNF-α–induced ICAM-1 expression in HMEC-1 (P = .040
at 800 kIU/mL and P < .001 at 1600 kIU/mL).
Aprotinin Inhibits Neutrophil Transmigration Across
TNF-α–Activated HUVECs
Neutrophils were allowed to migrate across resting or TNF-
α–activated lawns of HUVECs grown onto Transwell filter
inserts (3-µm pore size) in the presence and absence of
aprotinin. Figure 3 shows that exposure of HUVECs to
TNF-α for 4.5 hours resulted in an up-regulation of neu-
trophil transmigration, but this was significantly reduced by
pretreatment of the endothelial lawn for 60 minutes with
aprotinin (P = .046 at 1600 kIU/mL).
Discussion
We have focused on identifying an endothelial component
to the protective action of aprotinin during CPB-related
inflammation. Our results show that aprotinin blunts TNF-
induced ICAM-1 expression in ECs of both large vessel and
dermal microvascular origin. Furthermore, although TNF-
α–induced ICAM-1 and VCAM-1 levels are both inhibited
by aprotinin in HUVECs, E-selectin expression is not. The
possible functional relevance of these findings is indicated
Figure 2. Aprotinin inhibits ICAM-1 expression on microvascular
ECs. The dermal microvascular EC line, HMEC-1, was pretreated
with aprotinin for 60 minutes, rinsed, and then stimulated with
TNF-α as described in the legend to Figure 1. Results are
expressed as the mean ± SD fold increase over control.
Figure 3. Aprotinin inhibits neutrophil transmigration across TNF-
α–activated HUVECs. Lawns of HUVEC, grown onto Transwell fil-
ter inserts (3 µm pore size) by overnight culture, were pretreated
with aprotinin for 60 minutes, rinsed, and then stimulated with
TNF-α as described in the legend to Figure 1. After the TNF-α cul-
ture period, purified neutrophils were added to the upper chamber
and transendothelial migration was determined by counting the
number of neutrophils that had migrated across the HUVEC lawns
into the lower chamber. Results are expressed as the mean ± SEM
percentage of cells that had transmigrated in 60 minutes after
their addition (n = 4).
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by the ability of aprotinin to inhibit neutrophil transmigra-
tion across TNF-α–activated HUVECs.
The decrease in neutrophil trafficking may be due to
reduced ICAM-1 expression, because neutrophils do not use
the very late antigen-4:VCAM-1 axis but rely almost entire-
ly on binding of ICAM-1 to lymphocyte function–associat-
ed antigen-1 or macrophage antigen-1 to carry out firm
adhesion and extravasation.24 The firm adhesion step is
apparently not targeted by aprotinin, because neutrophil
adhesion, with the use of a parallel plate flow-chamber,
remains unchanged in the presence of aprotinin (data not
shown), consistent with previous in vivo work.18 It is
unlikely that proteases of a neutrophil origin were inadver-
tently targeted, because aprotinin was carefully washed
away from endothelial monolayers before the addition of
neutrophils. This washing step may also explain the require-
ment for a relatively high dose of aprotinin (1600 kIU/mL)
to achieve significant inhibition of transmigration compared
with levels used in the clinic (200 kIU/mL). Extrapolation
from the in vitro to the clinical situation is difficult, howev-
er, because previous studies have shown that although high
doses of aprotinin (800 and 1600 kIU/mL) are required to
inhibit neutrophil transmigration in vitro, much lower levels
(<200 kIU/mL) are required to achieve significant inhibition
in vivo.18
It is interesting to note that aprotinin specifically inhibit-
ed expression of the 2 immunoglobulin superfamily mole-
cules, ICAM-1 and VCAM-1, but not the selectin adhesion
molecule E-selectin. This was a surprise, because all 3
genes are known to be induced by similar NF-κB–depen-
dent signaling pathways and all are inhibitable by the
administration of dexamethasone. Our results suggest that a
protease-sensitive pathway may play a necessary role in
optimal ICAM-1 and VCAM-1 expression. Obvious candi-
date signaling receptors are the protease-activated receptor
(PAR) family,25 which includes the classic thrombin recep-
tor, PAR1, that we have previously shown is blocked by
aprotinin on platelets.26 ECs express PAR1 and PAR2,
which are activated by proteolytic cleavage with thrombin
and trypsin, respectively,27 and because aprotinin is known
to block these in vitro,28,29 it is possible that PAR activation
in HUVECs may contribute to the expression of ICAM-1
and VCAM-1. This possibility is supported by the fact that
overt stimulation through thrombin can up-regulate ICAM-
1 and VCAM-1 expression.30 The PARs are not strictly li-
gand-specific and can be activated by a wide variety of ser-
ine proteases, therefore leaving open the possibility that an
unknown protease of endothelial origin may be targeted by
aprotinin. Growing evidence that the PARs can be cofac-
tored by endothelial surface molecules in -cis further com-
plicates the picture but enhances the likelihood that these
receptors are involved, either directly or indirectly, in medi-
ating the effects reported here with aprotinin.31
The results presented here have added an endothelum-
specific dimension to the increasingly complex mechanism
of anti-inflammatory action of aprotinin in relation to CPB.
The wide distribution of protease targets within the coagu-
lation and fibrinolysis cascades, as well as the recent recog-
nition that cell-associated PARs may be targeted by apro-
tinin,26 may explain how aprotinin can achieve such diverse
anti-inflammatory effects at the level of (1) cytokine syn-
thesis, (2) contact activation of platelets and neutrophils, (3)
EC activation, and (4) leukocyte extravasation. Although it
will be important to evaluate future generations of protease
inhibitors with higher specific activity or longer half-life
than aprotinin, the attraction of aprotinin remains that as a
nonspecific serine protease inhibitor it can target a broad
range of substrates both in the soluble phase and associated
with the cell surface, which may prove beneficial in the
management of hemostasis and inflammation in CPB
surgery.
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